Patent intelligence · US
US 10519191
Bile acid analogs as FXR/TGR5 agonists and methods of use thereof
Bile acid analogs as FXR/TGR5 agonists and methods of use thereof
Patent details — US 10519191
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 31, 2019
- Expiration
- Dec 26, 2039
- Applicant
- Enanta Pharmaceuticals, Inc.
- Claims
- 13
- CPC classes
- A61P, A61P1/16
Quick answer
US 10519191 (Bile acid analogs as FXR/TGR5 agonists and methods of use thereof) is held by Enanta Pharmaceuticals, Inc.. Status: granted. Granted Dec 31, 2019. Expires Dec 26, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Enanta Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 13
- CPC classes
- A61P, A61P1/16
More from Enanta Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12384753
17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof
granted -
US 12358921
Antiviral heterocyclic compounds
granted -
US 12297209
Benzodiazepine derivatives as RSV inhibitors
granted -
US 12281140
Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
granted -
US 12268694
Combination pharmaceutical agents as RSV inhibitors
granted -
US 12264159
Functionalized heterocycles as antiviral agents
granted -
US 12162857
Antiviral compounds
granted -
US 12145941
Heterocyclic antiviral agents
granted
Frequently asked questions
What is US patent 10519191?
US 10519191 (Bile acid analogs as FXR/TGR5 agonists and methods of use thereof) is held by Enanta Pharmaceuticals, Inc.. Status: granted. Granted Dec 31, 2019. Expires Dec 26, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10519191?
Enanta Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 218 pharmaceutical patents for this assignee.
When does US 10519191 expire?
Our index shows an expiration date of Dec 26, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.